I spent some time today learning (trying to) a little about how ccr5 blocking helps fibrosis . After a study popped up.
AI explained how combined ccr2/ccr5 blockers are in trials now etc.
And when I asked if the combos will most likely be required. It told me a long explanation of how ccr2/ccr5 are closely linked when present on the cell and that leron has such ferocious (my word ) binding to ccr5, it partially blocks ccl2 linking.
And that blocking ccr2 also has side effects
My explanation is very bland compared.
Should I post it, its hard right after reading how it works not to post .
Sorry to chime in: Ill just do a little
Im not certain it applies to glio or your question, but it sounds like it might.
OHM is much more concise,
So skip the rest whoever hates AI analysis. I do too, but I dont have any other way to answer all the questions I have
Knowledge Mapping of Macrophages in Renal Fibrosis: A Bibliometric Analysis from 2014 to 2025
https://www.tandfonline.com/doi/full/10.2147/JIR.S578018
snip: Im leaving out a lot.
"In renal fibrosis, the biochemical dynamics shift slightly due to the unique cellular layout of the kidney, but the operational reality remains identical: a combined standalone CCR5/CCR2 antagonist will likely not be required if leronlimab is deployed at its maximum therapeutic footprint.
While the renal medical literature heavily emphasizes that the CCL2/CCR2 axis is a major driver of monocyte-to-macrophage recruitment during kidney injury, trying to use a separate chemical drug to block both gates introduces severe biological and clinical limitations. Leronlimab bypasses these hurdles through the exact same physical and microenvironmental mechanics that protect liver and tumor tissues.
..."The Leronlimab Intervention:
Because CCR2 and CCR5 physically pair up as heterodimers on the surface of infiltrating monocytes, leronlimab’s massive, high-affinity monoclonal antibody lock on the CCR5 side exerts an allosteric warp across the entire conjoined unit. This physical deformation locks up the adjacent CCR2 frame. Even as the kidney floods the tissue with CCL2, the signaling key can no longer cleanly engage the warped receptor, halting the MMT cascade without requiring a separate chemical antagonist"...
I also actually asked about ccl2 bypass apparently not working in our TNBC patients
Another snip:
“how did tumor not use ccl2 in the 5 survivors in tnbc to bypass ccr5”
The reason the tumors in those 5 long-term triple-negative breast cancer (TNBC) survivors failed to use the CCL2/CCR2 escape hatch to bypass the leronlimab blockade comes down to microenvironmental starvation and the "Prime and Pair" timing trap. [1, 2]
While a tumor cell wants to shift over to the CCL2 axis to recruit an alternate myeloid shield when CCR5 is blocked, it requires a highly active, un-disrupted stroma to execute that bypass. Leronlimab completely fractured that capability. [3]
The three primary reasons the CCL2 evasion loop was paralyzed in those specific patients map out as follows:
## 1. Chronic Depletion of the Macrophage Factory
TNBC tumors cannot simply generate a localized CCL2 shield out of thin air; they require an active influx of M2-polarized Tumor-Associated Macrophages (TAMs) to establish and secrete high levels of CCL2 in the stroma
The Result: The tumors were structurally starved. Without a continuous supply of incoming macrophages to build the cellular infrastructure, the localized concentration of CCL2 never reached the threshold necessary to trigger an alternative CCR2 escape hatch.
## 2. The Cytotoxic "Buddy Drug" Hammer
Those 5 survivors did not receive leronlimab as a standalone monotherapy; they were treated with leronlimab layered on top of a standard-of-care cytotoxic chemotherapy backbone. [1, 2]
* The Mechanism: While leronlimab handled the outer defenses, the chemotherapy aggressively hammered the internal mechanics of the dividing cancer cells.
* The Result: The rapid DNA-shredding action of the chemo completely paralyzed the tumor's ability to undergo the complex metabolic and genetic reprogramming required to upregulate and deploy alternative receptors (like CCR2). The tumor cells were dying too fast to activate their mutational backup switches.
## 3. The Immune Checkpoint "Finish Line" Trap
The ultimate reason these 5 patients achieved 5-year-plus durable survival is because leronlimab's blockade successfully forced the tumors into a state of intense cellular stress. [1]
[ Leronlimab Blocks CCR5 ] ───> [ Tumor Panics & Upregulates Surface PD-L1 ]
│
▼
[ 5+ Year Permanent Remission ] <─── [ ICI Buddy Drug Slams the Exposed Targets ]
* The Exposure: Instead of successfully executing a slow, chemokine-evasion bypass, the cornered tumor sheets panicked and pushed surface PD-L1 flags to their outer membranes. [1]
* The Execution: Because these patients were subsequently paired with an Immune Checkpoint Inhibitor (ICI), the buddy drug instantly clipped those PD-L1 cloaking devices. The patient's native, un-exhausted killer T-cells immediately flooded the core and executed a total, absolute clearance of the tumor tissue—wiping out the cancer completely before it ever had the tactical time to organize a secondary CCL2/CCR2 resistance loop
Thanks!
AI explained how combined ccr2/ccr5 blockers are in trials now etc.
And when I asked if the combos will most likely be required. It told me a long explanation of how ccr2/ccr5 are closely linked when present on the cell and that leron has such ferocious (my word ) binding to ccr5, it partially blocks ccl2 linking.
And that blocking ccr2 also has side effects
My explanation is very bland compared.
Should I post it, its hard right after reading how it works not to post .
Sorry to chime in: Ill just do a little
Im not certain it applies to glio or your question, but it sounds like it might.
OHM is much more concise,
So skip the rest whoever hates AI analysis. I do too, but I dont have any other way to answer all the questions I have
Knowledge Mapping of Macrophages in Renal Fibrosis: A Bibliometric Analysis from 2014 to 2025
https://www.tandfonline.com/doi/full/10.2147/JIR.S578018
snip: Im leaving out a lot.
"In renal fibrosis, the biochemical dynamics shift slightly due to the unique cellular layout of the kidney, but the operational reality remains identical: a combined standalone CCR5/CCR2 antagonist will likely not be required if leronlimab is deployed at its maximum therapeutic footprint.
While the renal medical literature heavily emphasizes that the CCL2/CCR2 axis is a major driver of monocyte-to-macrophage recruitment during kidney injury, trying to use a separate chemical drug to block both gates introduces severe biological and clinical limitations. Leronlimab bypasses these hurdles through the exact same physical and microenvironmental mechanics that protect liver and tumor tissues.
..."The Leronlimab Intervention:
Because CCR2 and CCR5 physically pair up as heterodimers on the surface of infiltrating monocytes, leronlimab’s massive, high-affinity monoclonal antibody lock on the CCR5 side exerts an allosteric warp across the entire conjoined unit. This physical deformation locks up the adjacent CCR2 frame. Even as the kidney floods the tissue with CCL2, the signaling key can no longer cleanly engage the warped receptor, halting the MMT cascade without requiring a separate chemical antagonist"...
I also actually asked about ccl2 bypass apparently not working in our TNBC patients
Another snip:
“how did tumor not use ccl2 in the 5 survivors in tnbc to bypass ccr5”
The reason the tumors in those 5 long-term triple-negative breast cancer (TNBC) survivors failed to use the CCL2/CCR2 escape hatch to bypass the leronlimab blockade comes down to microenvironmental starvation and the "Prime and Pair" timing trap. [1, 2]
While a tumor cell wants to shift over to the CCL2 axis to recruit an alternate myeloid shield when CCR5 is blocked, it requires a highly active, un-disrupted stroma to execute that bypass. Leronlimab completely fractured that capability. [3]
The three primary reasons the CCL2 evasion loop was paralyzed in those specific patients map out as follows:
## 1. Chronic Depletion of the Macrophage Factory
TNBC tumors cannot simply generate a localized CCL2 shield out of thin air; they require an active influx of M2-polarized Tumor-Associated Macrophages (TAMs) to establish and secrete high levels of CCL2 in the stroma
The Result: The tumors were structurally starved. Without a continuous supply of incoming macrophages to build the cellular infrastructure, the localized concentration of CCL2 never reached the threshold necessary to trigger an alternative CCR2 escape hatch.
## 2. The Cytotoxic "Buddy Drug" Hammer
Those 5 survivors did not receive leronlimab as a standalone monotherapy; they were treated with leronlimab layered on top of a standard-of-care cytotoxic chemotherapy backbone. [1, 2]
* The Mechanism: While leronlimab handled the outer defenses, the chemotherapy aggressively hammered the internal mechanics of the dividing cancer cells.
* The Result: The rapid DNA-shredding action of the chemo completely paralyzed the tumor's ability to undergo the complex metabolic and genetic reprogramming required to upregulate and deploy alternative receptors (like CCR2). The tumor cells were dying too fast to activate their mutational backup switches.
## 3. The Immune Checkpoint "Finish Line" Trap
The ultimate reason these 5 patients achieved 5-year-plus durable survival is because leronlimab's blockade successfully forced the tumors into a state of intense cellular stress. [1]
[ Leronlimab Blocks CCR5 ] ───> [ Tumor Panics & Upregulates Surface PD-L1 ]
│
▼
[ 5+ Year Permanent Remission ] <─── [ ICI Buddy Drug Slams the Exposed Targets ]
* The Exposure: Instead of successfully executing a slow, chemokine-evasion bypass, the cornered tumor sheets panicked and pushed surface PD-L1 flags to their outer membranes. [1]
* The Execution: Because these patients were subsequently paired with an Immune Checkpoint Inhibitor (ICI), the buddy drug instantly clipped those PD-L1 cloaking devices. The patient's native, un-exhausted killer T-cells immediately flooded the core and executed a total, absolute clearance of the tumor tissue—wiping out the cancer completely before it ever had the tactical time to organize a secondary CCL2/CCR2 resistance loop
Thanks!
7
